We report the preclinical development of a self-amplifying mRNA (SAM) vaccine encoding a prefusion stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein and demonstrate strong cellular and humoral immune responses at low doses in mice and rhesus macaques. The ...
COVID-19 boosters Professor Robin Shattock, who leads Imperial's COVID-19 vaccine project, said: "Global demand for COVID-19 vaccines will remain high in the coming decade, given the emergence of lethal SARS-CoV-2 escape-variants, and expected requirement for booster vaccination. We have show...
www.nature.com/npjvaccines ARTICLE OPEN A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability Emily A. Voigt 1 ✉, Alana Gerhardt2, Derek Hanson1, Madeleine F. Jennewein 1, Peter Battisti1, Sierra Reed2, Jasneet Singh1, Raodoh Mohamath3, Julie Bakken...
Japan has approved the world’s first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, although the manufacturer has not published safety or efficacy data for the shot. Tokyo-based Meiji Seika Pharma received approval for manufacturing and marketing its Kostaive sa-m...
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability Article Open access 02 November 2022 Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in health...
he notes, were initially developing a samRNA Covid-19 vaccine together, “but they decided to go quicker with the mRNAs because there was already some experience with the mRNAs in humans, so they thought it was going to be easier to get approval, while for the samRNA there was no ...
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma | CSLLY - CSL Ltd.
With the first wave of mRNA-based Covid-19 vaccines providing proof of concept to the entire field, investors are seeing dollar signs for platform plays once … Sign up to read this article for free. ...
Combination of waning immunity and lower effectiveness against new SARS-CoV-2 variants of approved COVID-19 vaccines necessitates new vaccines. We evaluated two doses, 28 days apart, of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, compared with saline placebo in an integrated phase 1/...
Coronavirus disease-19 (Covid-19) pandemic have demonstrated the importantance of vaccines in disease prevention. Self-amplifying mRNA vaccines could be another option for disease prevention if demonstrated to be safe and immunogenic. Phase 1 of this ran